IP
KPTI icon

Intellectus Partners’s Karyopharm Therapeutics KPTI Stock Holding History

Intellectus Partners’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-133
Closed -$12K – 307
2019
Q1 		$12K Buy
133
+80
+151% +$8.87K 0.01% 337
2018
Q4 		$7K Hold
53
– – ﹤0.01% 215
2018
Q3 		$14K Hold
53
– – ﹤0.01% 449
2018
Q2 		$14K Hold
53
– – 0.01% 451
2018
Q1 		$11K Hold
53
– – ﹤0.01% 468
2017
Q4 		$8K Hold
53
– – ﹤0.01% 501
2017
Q3 		$9K Hold
53
– – ﹤0.01% 626
2017
Q2 		$7K Hold
53
– – ﹤0.01% 636
2017
Q1 		$10K Hold
53
– – 0.01% 535
2016
Q4 		$8K Buy
+53
New +$7.17K ﹤0.01% 543

Other funds holding KPTI

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return

Intellectus Partners's KPTI Position: Q2 2019 in Review

Intellectus Partners sold out of Karyopharm Therapeutics (KPTI) in Q2 2019, closing a stake of 133 shares — an estimated $12K sold.

Intellectus Partners first reported a position in KPTI in Q4 2016 and held it in 10 quarters. The position peaked at $14K in Q3 2018. 103 funds tracked by Wall St. Rank hold KPTI as of Q2 2019.

  • Intellectus Partners reported no remaining Karyopharm Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Intellectus Partners sold 133 Karyopharm Therapeutics shares in Q2 2019, an estimated $12K.
  • Intellectus Partners first reported a position in Karyopharm Therapeutics in Q4 2016 and held it in 10 quarters.
  • Intellectus Partners's Karyopharm Therapeutics position peaked at $14K in Q3 2018.
  • 103 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2019.

Based on Intellectus Partners's 13F filing for Q2 2019, filed 8 Aug 2019.